Clinical proteomics in neurodegenerative disorders
- 6 June 2008
- journal article
- review article
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 118 (1), 1-11
- https://doi.org/10.1111/j.1600-0404.2007.00985.x
Abstract
Neurodegenerative disorders are characterized by neuronal impairment that eventually leads to neuronal death. In spite of the brain’s known capacity for regeneration, lost neurons are difficult to replace. Therefore, drugs aimed at inhibiting neurodegenerative processes are likely to be most effective if the treatment is initiated as early as possible. However, clinical manifestations in early disease stages are often numerous, subtle and difficult to diagnose. This is where biomarkers that specifically reflect onset of pathology, directly or indirectly, may have a profound impact on diagnosis making in the future. A triplet of biomarkers for Alzheimer’s disease (AD), total and hyperphosphorylated tau and the 42 amino acid isoform of β‐amyloid, has already been established for early detection of AD before the onset of dementia. However, more biomarkers are needed both for AD and for other neurodegenerative disorders, such as Parkinson’s disease, frontotemporal dementia and amyotrophic lateral sclerosis. This review provides an update on recent advances in clinical neuroproteomics, a biomarker discovery field that has expanded immensely during the last decade, and gives an overview of the most commonly used techniques and the major clinically relevant findings these techniques have lead to.Keywords
This publication has 85 references indexed in Scilit:
- Clearance of amyloid-β by circulating lipoprotein receptorsNature Medicine, 2007
- Fibrinogen gamma-A chain precursor in CSF: a candidate biomarker for Alzheimer's diseaseBMC Neurology, 2007
- Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometryNature Methods, 2007
- Cystatin C in cerebrospinal fluid and multiple sclerosisAnnals of Neurology, 2006
- Diagnosing prodromal Alzheimer's disease: Role of CSF biochemical markersMechanisms of Ageing and Development, 2006
- Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseasesNeuroscience Letters, 2004
- Mass spectrometry-based proteomicsNature, 2003
- Empirical Statistical Model To Estimate the Accuracy of Peptide Identifications Made by MS/MS and Database SearchAnalytical Chemistry, 2002
- Identification of oxidized plasma proteins in Alzheimer's diseaseBiochemical and Biophysical Research Communications, 2002
- High Levels of Circulating Aβ42 Are Sequestered by Plasma Proteins in Alzheimer's DiseaseBiochemical and Biophysical Research Communications, 1999